Snapshot from Sep 15, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug recall

SAHPRA recalls Arya Pharma Enalapril 10mg

Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 29, 2026

Sentiment
-10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The recall may temporarily disrupt supply of Enalapril 10mg in South Africa, but the availability of the 5mg alternative mitigates patient impact. Arya Pharma faces reputational and regulatory scrutiny, while Austell Pharmaceuticals may benefit from increased demand for its product.

Pharmaceuticals Healthcare

The South Africa — South African Health Products Regulatory Authority (SAHPRA) ordered a recall of four batches of Enalapril 10mg tablets manufactured by Arya Pharma due to a potency issue identified during post-marketing surveillance. The affected batches, produced in September and October 2024, were found to not meet the required milligram strength, potentially making them less effective. The South Africa — Department of Health (South Africa) reassured patients that the recall does not affect the 5mg version of the drug, which is supplied to public health facilities and has been confirmed to meet quality standards. The 10mg tablets had been approved only as a temporary alternative while the contracted supplier, Austell Pharmaceuticals, resolved a delay in releasing its 5mg product. Patients were urged to continue taking their medication as prescribed.

priv
Arya Pharma is the manufacturer of the recalled 10mg tablets. The recall due to potency issues could damage its reputation and lead to financial losses, regulatory penalties, or loss of contracts.
Importance 100.0 Sentiment -40.0
govactor
SAHPRA initiated the recall, demonstrating regulatory vigilance. This action reinforces its role in ensuring drug quality but may also raise concerns about oversight of temporary approvals.
Importance 90.0 Sentiment 10.0
govactor
The department managed the public response, reassuring patients and coordinating with SAHPRA to confirm the safety of the 5mg tablets. Its role is central to maintaining public trust and continuity of care.
Importance 80.0 Sentiment -10.0
cnt
The recall affects the South African public health system and patients relying on Enalapril. The government's response aims to minimize disruption and maintain access to essential medication.
Importance 70.0 Sentiment -10.0
priv
Austell is the contracted supplier of the 5mg tablets, which remain unaffected. The recall may increase demand for its product and reinforce its position as a reliable supplier.
Importance 60.0 Sentiment 20.0
per
As departmental spokesperson, Mohale communicated the reassurance and clarified the scope of the recall. His statements helped prevent public panic and ensured continuity of treatment.
Importance 40.0 Sentiment 0.0
per
As SAHPRA spokesperson, Baloyi explained the reason for the recall, citing potency issues. His role was to provide transparency about the regulatory action.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.